Clinical Gastroenterology and Hepatology Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis  Ikuo Hirano, Evan S. Dellon, Margaret H. Collins, James Williams, Lan Lan, David A. Katzka  Clinical Gastroenterology and Hepatology  DOI: 10.1016/j.cgh.2018.11.045 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Patient demographics and disease characteristics at the start of randomization are presented and were stratified by placebo response status during the last 2 weeks of the 4-week, single-blind, placebo run-in period. (A) Proportion of patients on concomitant medication; (B) proportion of patients with EREFS features; (C) proportion of patients with each EREFS feature grade (severity) score*; and (D) mean peak eosinophil counts.‡ Responders were defined as having a reduction of ≥30% in DSQ score during the final 2 weeks of the placebo run-in. *Higher scores indicate increased levels of severity for that EREFS feature. ‡Responders during the placebo run-in: proximal, n = 21; mid, n = 23; distal, n = 24; non-responders during the placebo run-in: proximal, n = 63; mid, n = 67; distal, n = 69. DSQ, Dysphagia Symptom Questionnaire; eos, eosinophils; EREFS, endoscopic reference score; hpf, high-power field; PPI, proton pump inhibitor; SD, standard deviation. Clinical Gastroenterology and Hepatology DOI: (10.1016/j.cgh.2018.11.045) Copyright © 2018 AGA Institute Terms and Conditions

Supplementary Figure 1 ▪▪▪. Clinical Gastroenterology and Hepatology DOI: (10.1016/j.cgh.2018.11.045) Copyright © 2018 AGA Institute Terms and Conditions